A new study from MUSC Hollings Cancer Center researchers shows, for the first time, that a receptor called PPAR δ, or ...

Researchers have uncovered a new pathway that enables cancer cells to grow unchecked by disabling the immune system.

Table 1 Selected PPAR-targeted drugs in Phase II or III trials * Full size table Many research groups have “been fishing with the wrong bait” in trying to develop effective and safe anti ...

Fibrates are widely prescribed agonists of transcription factor peroxisome proliferator-activated receptor (PPAR)-α, and are used to treat patients with atherogenic dyslipidemia. These drugs ...

A new study from MUSC Hollings Cancer Center researchers shows, for the first time, that a receptor called PPAR δ, or ...

Tempest Therapeutics (NASDAQ:TPST) shares dropped Thursday after the company updated data from an ongoing trial designed to test its PPAR⍺ antagonist, amezalpat (TPST-1120), as a first-line ...

Ipsen announced today that the National Institute for Health and Care Excellence (NICE) has recommended elafibranor 80mg ...

ETNB has a solid financial runway but faces risks from GLP-1 data and competition within the FGF21 space, making it a Hold ...

代谢相关脂肪性肝病（MAFLD）及其严重类型代谢相关脂肪性肝炎（MASH）在全球范围内呈现出逐年攀升的发病趋势，已成为威胁人类肝脏健康的重大挑战。在2024年中国国际进口博览会医疗器械及 ...

编者按：随着全球肝脏疾病谱的改变，原发性胆汁性胆管炎（PBC）的发病率也逐年增高，我国PBC的疾病流行率已达亚太地区最高。在第十届“丝路肝病”学术会议上，空军军医大学西京医院韩英教授作题为《难治性原发性胆汁性胆管炎的早诊及干预策略》的精彩报告，本刊特 ...

2024年11月1日，微芯生物披露接待调研公告，公司于10月31日接待兴业证券、国盛证券、中信建投、广发证券、华西证券等52家机构调研。